Anders Erik Astrup Dahm

7PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersRespiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)Comparative physiologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 21, 2022
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply.

Trine-Lise Larsen, Herish Garresori, Jorunn Brekke

|Feb 03, 2022
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.

Trine-Lise Larsen, Herish Garresori, Jorunn Brekke

|Jul 02, 2021
Cancer and Thrombosis: New Treatments, New Challenges.

Anders Erik Astrup Dahm

|Jun 04, 2021
Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?

Anders Erik Astrup Dahm, Per Morten Sandset

|May 20, 2021
Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta-analysis.

Christopher Friis Berntsen, Pernille Rootwelt, Anders Erik Astrup Dahm

|Mar 28, 2021
Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.

Deeksha Khialani, Sowmya Vasan, Mary Cushman

Pageof 2

Frequent Collaborators

4 joint publications

Per Morten Sandset

2 joint publications

Waleed Ghanima

2 joint publications

Trine-Lise Larsen

2 joint publications

Anne Hansen Ree